Leerink Partnrs Has Strong Estimate for ASND FY2024 Earnings

Ascendis Pharma A/S (NASDAQ:ASND) – Equities research analysts at Leerink Partnrs upped their FY2024 earnings estimates for shares of Ascendis Pharma A/S in a research note issued on Monday, January 20th. Leerink Partnrs analyst J. Schwartz now expects that the biotechnology company will earn ($6.44) per share for the year, up from their prior estimate of ($6.50). The consensus estimate for Ascendis Pharma A/S’s current full-year earnings is ($7.12) per share. Leerink Partnrs also issued estimates for Ascendis Pharma A/S’s Q4 2024 earnings at ($0.26) EPS, Q1 2025 earnings at ($1.90) EPS, Q2 2025 earnings at ($1.81) EPS, Q3 2025 earnings at ($1.74) EPS, Q4 2025 earnings at ($1.66) EPS, FY2025 earnings at ($7.12) EPS and FY2026 earnings at ($2.00) EPS.

A number of other analysts have also commented on the company. StockNews.com raised Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th. Oppenheimer cut their price objective on shares of Ascendis Pharma A/S from $190.00 to $180.00 and set an “outperform” rating for the company in a research report on Friday, November 15th. Wedbush restated an “outperform” rating and set a $181.00 target price on shares of Ascendis Pharma A/S in a research report on Friday, November 15th. Stifel Nicolaus lifted their target price on shares of Ascendis Pharma A/S from $200.00 to $207.00 and gave the stock a “buy” rating in a research note on Friday, November 15th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $170.00 price target on shares of Ascendis Pharma A/S in a research note on Friday, November 15th. Two investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $192.07.

Ascendis Pharma A/S Price Performance

Shares of Ascendis Pharma A/S stock opened at $125.82 on Wednesday. The business has a 50 day moving average price of $133.19 and a 200 day moving average price of $133.34. The company has a market capitalization of $7.64 billion, a P/E ratio of -15.57 and a beta of 0.65. Ascendis Pharma A/S has a 1 year low of $111.09 and a 1 year high of $161.00.

Institutional Trading of Ascendis Pharma A/S

A number of hedge funds and other institutional investors have recently modified their holdings of ASND. Blue Trust Inc. grew its stake in Ascendis Pharma A/S by 540.5% during the 4th quarter. Blue Trust Inc. now owns 506 shares of the biotechnology company’s stock valued at $76,000 after purchasing an additional 427 shares in the last quarter. SG Americas Securities LLC increased its stake in shares of Ascendis Pharma A/S by 410.4% in the fourth quarter. SG Americas Securities LLC now owns 33,944 shares of the biotechnology company’s stock worth $4,673,000 after buying an additional 27,293 shares during the last quarter. ARS Investment Partners LLC raised its holdings in Ascendis Pharma A/S by 0.9% in the fourth quarter. ARS Investment Partners LLC now owns 265,480 shares of the biotechnology company’s stock valued at $36,549,000 after acquiring an additional 2,369 shares in the last quarter. Crossmark Global Holdings Inc. boosted its stake in Ascendis Pharma A/S by 28.5% during the 4th quarter. Crossmark Global Holdings Inc. now owns 10,435 shares of the biotechnology company’s stock valued at $1,436,000 after acquiring an additional 2,315 shares during the last quarter. Finally, Diversified Trust Co grew its holdings in Ascendis Pharma A/S by 7.4% during the 4th quarter. Diversified Trust Co now owns 45,038 shares of the biotechnology company’s stock worth $6,200,000 after acquiring an additional 3,114 shares in the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.